Carpe Diem S.R.L.
- Address
- Strada Negruzzi Costache No.12, 550281 Sibiu, Romania
Carpe Diem S.R.L. - Neurodegenerative and Psychiatric Disorders Research
Carpe Diem S.R.L. is a specialized clinical research center with demonstrated expertise in conducting advanced trials for neurodegenerative and psychiatric disorders. The center has established a strong focus on complex neuropsychiatric conditions, particularly those involving cognitive and behavioral symptoms in vulnerable patient populations. Their research portfolio emphasizes innovative therapeutic interventions targeting both the psychiatric and neurocognitive aspects of severe mental health conditions.
- Psychosis and agitation associated with Alzheimer's disease, utilizing specialized assessment tools including the NPI-C and BEHAVE-AD scales
- Cognitive impairment in schizophrenia, with extensive experience in long-term safety monitoring and Phase III clinical trial programs
- Novel pharmacological interventions for neuropsychiatric symptoms in dementia and primary psychotic disorders
The center demonstrates particular proficiency in evaluating behavioral and psychological symptoms of dementia (BPSD), including both psychotic features and agitation in Alzheimer's disease populations. Their research capabilities extend to comprehensive long-term safety assessments and the use of validated psychiatric rating instruments such as the Cohen-Mansfield Agitation Inventory (CMAI) and Neuropsychiatric Inventory-Clinician assessments. This expertise positions Carpe Diem S.R.L. as a valuable contributor to the development of breakthrough therapies for patients suffering from neurodegenerative diseases with complex psychiatric manifestations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Intra-Cellular Therapies Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Intra-Cellular Therapies Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Carpe Diem S.R.L.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of ITI-1284 in Psychosis Associated with Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Intra-Cellular Therapies Inc. | Phase II | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Iti-1284 | 2 | Unknown | 2025-07-11 | 2025-07-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.